Endsulin Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 5
Employees
  • Latest Deal Type
  • Series A
  • (Upcoming)
  • Investors
  • 1

Endsulin General Information

Description

Provider of medical research services intended to cure Type I Diabetes with gene therapy. The company's services are primarily engaged in discovering glucose-inducible insulin transgene (glucose inducible responsive element, or GIRE) and a method for obtaining glucose-regulated expression of active insulin in mammalian cells, enabling patients to precisely regulate insulin on their own by re-coding a small fraction of their liver to function like a pancreas.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Primary Office
  • 504 South Rosa Road
  • Suite 200
  • Madison, WI 53719
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Endsulin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) Upcoming Product Development
1. Angel (individual) Completed Startup
To view Endsulin’s complete valuation and funding history, request access »

Endsulin Executive Team (5)

Name Title Board Seat Contact Info
Eric Spyra President & Board Member
Adam Bock Ph.D Chief Financial Officer
Hans Sollinger MD Co-Founder, Interim CSO & Board Member
Dylan Schweitzer Corporate Development Associate
You’re viewing 4 of 5 executive team members. Get the full list »

Endsulin Board Members (4)

Name Representing Role Since
Elizabeth Aden Ph.D Endsulin Board Member 000 0000
Eric Spyra Endsulin President & Board Member 000 0000
Hans Sollinger MD Endsulin Co-Founder, Interim CSO & Board Member 000 0000
Thomas Dee Self Board Member 000 0000
To view Endsulin’s complete board members history, request access »

Endsulin Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endsulin Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Jeffrey Rusinow Angel (individual) Minority 000 0000 000000 0
To view Endsulin’s complete investors history, request access »